Biogen Q4 Earnings Beat Expectations, 2026 Profit Outlook Strong
ByAinvest
Friday, Feb 6, 2026 7:12 am ET1min read
BIIB--
Biogen reported Q4 2025 earnings that beat expectations, with adjusted EPS of $1.99 and revenue of $2.28 billion, surpassing analyst estimates. The biotech company's shares rose 1.4% following the announcement. For 2026, Biogen expects adjusted EPS between $15.25 and $16.25 and total revenue to decline by a mid-single digit percentage compared to 2025. Growth products showed continued momentum, with LEQEMBI's global in-market sales reaching approximately $134 million, up 54% YoY.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet